Cellonis Biotechnologies Co.Ltd
logo北京弘潤天源生物技術有限公司是專門從事細胞治療技術研究與細胞治療臨床套用的專業化生物技術公司，是北京市中關村高新技術企業、北京市海淀區創新企業。公司以北京大學技術團隊為核心。公司主要致力於人成體幹細胞、樹突狀細胞治療的研究與套用，通過與臨床醫院的全面合作，開展細胞治療的臨床套用服務。
目前公司擁有符合臨床治療需要的全部細胞類型，包括神經幹細胞、視網膜上皮祖細胞、臍帶和自體骨髓間充質幹細胞、肝臟幹細胞、樹突狀細胞和細胞因子誘導的殺傷細胞，是技術平台最完整的公司之一。其中神經幹細胞貼壁培養技術、視網膜上皮祖細胞培養技術、肝臟幹細胞培養技術、腫瘤幹細胞培養技術、放化療耐藥細胞培養技術在國內外均為領先。公司已就腫瘤幹細胞及腫瘤幹細胞疫苗申報國家專利（專利申請號：200910082778.0，200910083085.3）
公司秉承“為細胞治療事業的發展實施最好推廣、追求最佳服務”的運營理念，圍繞臨床治療的細胞供應和臨床服務兩個環節，以技術支持、細胞供應、科研服務（臨床研究和諮詢、課題合作）為服務方式，結合構建各地區生產中心的細胞生產網路為運營模式，實現產業化發展。
公司擁有通過SFDA認證的GMP生產車間並配置先進的細胞生產設備，擁有系統的細胞生產管理規範與管理制度，為細胞的臨床套用提供了有效的保障。
公司作為一家運作細胞治療的高科技生物公司，有著清晰的管理組織結構和一大批優秀人才。在技術方面擁有多項領先的專利技術和一批高端的技術專家團隊；在臨床方面我們與國內多所醫院的一批臨床專家形成密切合作，積極推進各類疾病的規範化細胞治療。公司現階段的細胞治療範圍主要集中在：成體幹細胞治療神經系統疾病、骨科疾病、外周血管病；樹突狀細胞治療惡性腫瘤。
公司官網：www.cellonis.com
Cellonis Biotechnologies Group is a China based biotechnology company focus primarily on the development and applying of novel stem cell technologies for providing the effective, patient-specific therapies to patients with degenerative central nervous system (CNS) disorders, cardiovascular diseases, liver diseases and cancers.
Based on the over 5 years experience of extensive research and treatment protocol development, we have built up an advance stem cell platform technology and more than 5 stem cell therapy programs have been used by partner hospitals for clinical research and treatment.
We have gotten the promising results from the clinical trails with our lead autologous adult stem cell and neural stem cell therapy programs for different kinds of CNS disorders such as parkinson's disease, post stroke, cerebral palsy, ALS (motor neuron disease), MS (multiple sclerosis), brain injury and spinal cord injury (SCI). And more than 100 patients experienced the stem cell therapy with our therapy programs. In addition to our CNS disorder programs, we are developing stem cell approaches for other conditions, including the liver diseases（hepatitis and cirrhosis.）, heart failure and peripheral artery diseases.
Cellonis is also advancing the cancer vaccine and cellular therapy for cancer. Our cancer vaccine programs which target at different kinds of solid tumor cells have showed great potential in cancer treatment. Currently Cellonis is exploring the novel cell therapies with the integration of its core stem cell technologies and immune technologies. The patented technologies will allow Cellonis to develop more effective cellular approaches for cancer relapse and metastasis.
Our headquarters and main facilities are located in Beijing. SinoTopCell Limited is a wholly-owned subsidiary of Cellonis located in Hong Kong focus on the international technology development and collaboration.
web site:www.cellonis.com
